Boston Scientific: Market Pessimism Has Created a Tactical Long Opportunity
Shares of Boston Scientific (BSX) sit nearer the 52-week low after a pronounced pullback from the $105 peak. Fundamentals remain intact - $3.62B in free cash flow, a conservative debt-to-equity of 0.51 and a P/E near 17.5 - and recent negative sentiment appears overstated versus the firm's product pipeline and cash generation. This trade idea outli…